IGF

This engineered LR3 analog bypasses inhibitory binding proteins to provide sustained IGF-1 receptor activation in complex tissue models, supporting cell growth & regeneration signaling.

$140.00

Collections

Review Third-Party Certificates of Analysis:

COA

Core Analytical Specifications:

Chemical Purity Assay

Net Mass Verification

Microbial Sterility Screening

Endotoxin (LPS) Detection

Verified
Purity
Thresholds

Independent
COA
Validation

Secure
Trackable
Shipping

Synthesized, Analytically Verified, and Dispatched from United States.

Molecular Design & Functional Mechanism

IGF-1 LR3 is an engineered IGF-1 analog commonly described as having reduced binding to IGF binding proteins (IGFBPs) and altered kinetics, supporting experiments focused on IGF-1 receptor signaling and proliferative pathways. 

What Research Shows 

  • Cell culture performance: Commercial technical descriptions emphasize enhanced cell-culture performance and potency relative to insulin in certain contexts (application-dependent). 
  • Mechanistic signaling rationale: Public technical summaries describe LR3 sequence modifications and framing around extended activity and receptor-level signaling experiments. 

Why Research Teams Choose IGF-1 LR3

  • High-signal growth pathway tool: Useful in proliferation, differentiation, and tissue repair modeling where IGF signaling is central.
  • Cell culture utility: Commonly selected to drive consistency in serum-reduced culture conditions and production workflows (context-specific).
Molecular Design & Functional Mechanism

Tirzepatide is engineered to activate GIPR + GLP-1R simultaneously, enabling coordinated incretin signaling for appetite regulation, glycemic physiology, and energy-balance research. The clinical program positions it as a high-ceiling comparator for next-gen incretin work.

Tirzepatide is engineered to activate GIPR + GLP-1R simultaneously, enabling coordinated incretin signaling for appetite regulation, glycemic physiology, and energy-balance research. The clinical program positions it as a high-ceiling comparator for next-gen incretin work.

Tirzepatide is engineered to activate GIPR + GLP-1R simultaneously, enabling coordinated incretin signaling for appetite regulation, glycemic physiology, and energy-balance research. The clinical program positions it as a high-ceiling comparator for next-gen incretin work.

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. Foundation Plus supplies compounds intended for laboratory research and development purposes. Products are not promoted for consumer, medical, or veterinary use. These products are not drugs, food additives, or dietary supplements and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.

Related Products

Leave a review

Compliance & Age Verification

Access to the Foundation Plus digital storefront is strictly restricted to individuals 21 years of age or older.

The compounds available on this site are intended solely for laboratory research purposes. These materials are not designed to prevent, treat, or cure any medical condition and are strictly not for human consumption. By entering this site, you verify that you meet the age requirement, acknowledge these clinical restrictions, and possess a legitimate research basis for the procurement of these products.

Please note that all compounds are provided as individual units.

I am under 21 / Exit